Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.
Retrieved on:
Tuesday, October 17, 2023
Science, Biotechnology, Research, Health, Hospitals, Genetics, Vitamins, Supplements, Clinical Trials, Molecular Therapy, Congress, Multimedia, Death, Plasma, Beta-glucan, National Center for Health Research, Scientific Reports, Inflammation, Trial of the century, DMD, Safety, NSAA, Disease, Pulmonary fibrosis, Patient, Allergen, Nature, Heart failure, Head, Neurology, Cardiac fibrosis, Clinical trial, MDX, Mouse, Duchenne muscular dystrophy, Pathology, Fibrosis, Multisystemic smooth muscle dysfunction syndrome, Myositis, MRC, Dietary supplement, Pharmaceutical industry, Psychiatry
This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.
Key Points:
- This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.
- of Molecular Therapy, National Center for Neurology and Psychiatry (NCNP), Tokyo, Japan, a pioneer in developing solutions to DMD such as exon skipping therapy .
- The findings published in Scientific Reports, a publication by Nature portfolio also reported a reduction in muscle inflammation, which precedes fibrosis and muscle dysfunction, leading gradually to respiratory muscle failure followed by lung dysfunction, cardiac fibrosis, heart failure and premature death.
- With additional experiments in MDX mice underway , as more data evolves, that may be value adding to recommend Neu REFIX β-glucan to DMD patients, said Dr Yoshitsugu Aoki.